Evidence map›Paper›PMID 42451758›Full record

ReviewMolecules (Basel, Switzerland)2026

Animal- and Plant-Derived Protein Nanocarriers for the Delivery of Natural Compounds in Breast Cancer Chemoprevention.

Zuzanna Senkowska, Julia Wojtkowicz, Dominik Zakrzewski, Katarzyna Owczarek, Karolina Niewinna, Urszula Lewandowska

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zuzanna SenkowskaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0009-0006-1243-721X
Julia WojtkowiczDepartment of Medical Biology, Faculty of Pharmacy, Medical University of Lodz, 90-151 Lodz, Poland.ORCID 0009-0009-7913-5912
Dominik ZakrzewskiDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0009-0004-1004-4637
Katarzyna OwczarekDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-1351-2406
Karolina NiewinnaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-4404-3243
Urszula LewandowskaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-5995-6168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, highlighting the need for safer and more effective chemopreventive strategies. Although many phytochemicals can modulate key molecular processes involved in breast carcinogenesis, their chemopreventive potential largely depends on delivery strategies that preserve their biological activity and enable efficient accumulation at the target site. Protein-based nanocarriers have emerged as promising delivery systems capable of improving the protection, solubility, cellular uptake, targeted delivery, and controlled release of bioactive compounds in tumor tissues. This review summarizes recent advances in selected animal- and plant-derived protein nanocarriers used for the encapsulation and delivery of natural compounds in breast cancer chemoprevention. Particular attention is given to their physicochemical properties, encapsulation performance, release behavior, biological activity, targeting potential, and translational limitations. Furthermore, the mechanisms underlying the enhanced anticancer activity of encapsulated phytochemicals, including improved stability, receptor-mediated uptake, pH-responsive release, apoptosis induction, oxidative stress modulation, and inhibition of tumor growth and metastasis, are highlighted. Current challenges, including enzymatic degradation, formulation instability, immunogenicity concerns, manufacturing scalability, and limited clinical evidence, remain important barriers to translation. Overall, selected protein-based nanocarriers represent promising multifunctional platforms for improving the chemopreventive potential of natural compounds in breast cancer.

Indexed as

Biological ProductsBreast NeoplasmsDrug CarriersNanoparticlesPlant ProteinsAnimalsAnticarcinogenic AgentsChemopreventionDrug Delivery SystemsFemaleHumansPhytochemicalsAnticarcinogenic AgentsBiological ProductsDrug CarriersPhytochemicalsPlant Proteinsbioavailabilitybreast cancerchemopreventionencapsulationnanocarrierspolyphenolsprotein-based nanocarriers

Identifiers

PMID42451758
PMCPMC13362689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.